Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.

Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.

Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.

Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.

Abstract: The present invention is directed toward adjuvants that effect an innate and/or a specific immune response. The adjuvants contain at least one lipoprotein, such as Lip, Lip fragments or Lip variants, where the lipoprotein comprises at least one pentameric unit and at least one lipid moiety. Adjuvants wherein the lipoprotein make up at least 10% of the adjuvant by weight/volume are provided.

Abstract: The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a Shigella outer membrane protein (OMP) and Shigella LPS molecule in medicine and methods for preparing the composition.

Abstract: The invention provides a TLR agonist and an antibody which binds to an antigen such as a ?-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease.

Abstract: The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) 7 agonist in an orally (e.g. sublingually) administered composition.

Abstract: The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a Shigella outer membrane protein (OMP) and Shigella LPS molecule in medicine and methods for preparing the composition.

Abstract: The present invention relates to methods and compositions for preventing and reducing amyloid deposition in a subject by administering to the subject a composition containing aTLR4 agonist free of endotoxin, where the composition does not contain beta amyloid.

Abstract: The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) agonist in an orally (e.g. sublingually) administered composition.

Abstract: The invention provides a TLR agonist and an antibody which binds to an antigen such as a ?-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease.

Abstract: Compositions and methods comprising or using a combination of an adjuvant such as AS01B and an antigen such as a ?-amyloid antigen are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's disease. Suitable ?-amyloid antigens are A?1-5, A?1-6, A?1-7, A?1-10, A?1-14, A?1-15, A?2-7, A?2-8, A?3-7, A?3-8, A?11-16, A?11-17, A?p(E)3-7, A?p(E)3-8, A?p(E)3-40, A?p(E)3-42, A?p(E)11-16, A?p(E)11-17, A?p(E)11-40 or A?p(E)11-42, optionally with a protein carrier. Suitable adjuvants comprise QS21, 3D-MPL or an AGP, optionally in combination with a liposome.

Abstract: The present invention is directed toward adjuvants that effect an innate and/or a specific immune response. The adjuvants contain at least one lipoprotein, such as Lip, Lip fragments or Lip variants, where the lipoprotein comprises at least one pentameric unit and at least one lipid moiety. Adjuvants wherein the lipoprotein make up at least 10% of the adjuvant by weight/volume are provided.

Abstract: A mold apparatus for manufacturing a surface patterned block. The apparatus includes a resilient template with a relief pattern supported in a support frame. A setting substrate is supported in the support frame and on the cloth template and has at least one moldable surface. The relief pattern contacts the moldable surface and transfers the relief pattern to the moldable surface to form the surface patterned block. A method of producing a patterned block and a patterned block are also provided.